By Jason Derry --
Novocell Inc. recently announced that it has received an additional $25 million in funding from a number of its stakeholders, including Johnson & Johnson Development Corp., Sanderling Ventures, Asset Management Co., and Pacific Horizon Ventures. Novocell is located in San Diego, and focuses on stem cell research. Its primary objective at this time is to use endoderm cells, generated from embryonic stem cells, to stimulate insulin production in diabetes patients. According to Novocell's president and chief scientific officer, the new funding will be used in large part to move its insulin program forward in clinical development.
Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.
Comments